Unlocking the Potential of AOC4P: A Pseudogene for Drug Targets and Biomarkers

Target Name: AOC4P

NCBI ID: G90586

AOC4P

Other Name(s): amine oxidase copper containing 4, pseudogene | Amine oxidase copper containing 4, pseudogene | UPAT | AOC4

Unlocking the Potential of AOC4P: A Pseudogene for Drug Targets and Biomarkers

Amino acid oxidase (AO) enzymes are critical regulators of cellular metabolism, catabolism, and stress responses. The family of AO enzymes, which includes the pseudogene AOC4P, plays a crucial role in various cellular processes. In this article, we will explore the potential of AOC4P as a drug target and biomarker.

The AOC4P Pseudogene

The AOC4P pseudogene is a gene that encodes a protein known as AOC4P (amine oxidase copper containing 4). This protein is expressed in various tissues, including liver, muscle, heart, kidney, and brain, and is involved in the detoxification of amines, which are toxic substances that can cause a range of cellular and molecular changes.

AOC4P is a single-chain protein that contains 46 amino acids. Its unique feature is the presence of a copper atom, which plays a crucial role in its catalytic activity. Copper ions are well-known for their catalytic properties and are often used as catalysts in various cellular processes. The copper atom in AOC4P functions as a reducing agent, which enables the efficient reduction of amines to their less toxic forms.

Drug Target Potential

The drug targeting of AOC4P is an attractive idea due to its unique structure and the involvement of a copper atom in its catalytic activity. AOC4P has been shown to be a promising drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the potential drug targets for AOC4P is cancer. Cancer cells often produce high levels of amines, which can lead to the formation of reactive oxygen species (ROS) that contribute to the development and progression of cancer. AOC4P has been shown to reduce the production of ROS by activating the cellular antioxidant system. Therefore, AOC4P could be a useful drug target for cancer therapy.

Another potential drug target for AOC4P is neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. AOC4P has been shown to promote the production of neuroprotective antioxidants, which may help to alleviate the oxidative stress caused by the buildup of neurofibrillary tangles.

Biomarker Potential

In addition to its potential as a drug target, AOC4P also has the potential as a biomarker for various diseases. For example, AOC4P has been shown to be elevated in the brains of individuals with Alzheimer's disease, and its levels have been linked to the severity of the disease. Similarly, AOC4P has been shown to be elevated in the urine and plasma of individuals with Parkinson's disease, which may indicate the presence of neurodegeneration.

Conclusion

In conclusion, AOC4P is a pseudogene that encodes a protein involved in the detoxification of amines. Its unique feature is the presence of a copper atom, which plays a crucial role in its catalytic activity. Based on its potential as a drug target and biomarker, AOC4P is an attractive target for future research and development.

Protein Name: Amine Oxidase Copper Containing 4, Pseudogene

The "AOC4P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AOC4P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets